The US Supreme Court has refused to look at the result of a federal lawsuit between GSK and Teva over so-called ‘skinny labels’ for generic drugs, despite a request from t
The White House has told the US Supreme Court that it should hear a hotly-contested lawsuit between Teva and GSK that could have ramifications on the ability of generic dr
GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophyla
Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-sell
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio